Clinical Trial: Tysabri® (natalizumab) - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: Tysabri® (natalizumab)

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 300
Medication: Tysabri
Location: AL|AZ|CA|CO|DE|DC|FL|GA|IL|IN|KS|KY|MA|MI|NY|NC|OH|OR|PA|TX|UT|VA|WA
Contact Information
neurologyclinicaltrials@biogenidec.com

Funding:

Biogen Idec

Description

A multicenter, observational, open label study of to determine effectiveness in early relapsing remitting multiple sclerosis.

Share